<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03920813</url>
  </required_header>
  <id_info>
    <org_study_id>2018Mercaptopurine001</org_study_id>
    <nct_id>NCT03920813</nct_id>
  </id_info>
  <brief_title>Determinants of Mercaptopurine Toxicity in Paediatric Acute Lymphoblastic Leukemia Maintenance Therapy</brief_title>
  <official_title>Determinants of Mercaptopurine Toxicity in Paediatric Acute Lymphoblastic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study was conducted to assess the population pharmacokinetics of 6-mercaptopurine
      (6-MP) in Pediatric Acute Lymphoblastic Leukemia (ALL) and genetic polymorphisms
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators' purpose was to identify genetic factors and metabolite concentrations
      associated with both hematological toxicity in patients with ALL maintained on 6-MP in
      Chinese.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Red blood cells (RBC) concentration of 6-mercaptopurine (6-MP)</measure>
    <time_frame>at second day after oral administration</time_frame>
    <description>To detect of RBC 6-MP metabolite concentrations and evaluate the association of metabolite concentrations and side effects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Genetic polymorphisms in Chinese patients with ALL</measure>
    <time_frame>at second day after oral administration</time_frame>
    <description>To detect the frequencies of genetic polymorphisms of Chinese patients receiving 6-MP for treatment of ALL</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Antitumor drugs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mercaptopurine administered at standard dose for children with hematological neoplasms.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mercaptopurine</intervention_name>
    <description>Dose of mercaptopurine was adjusted to maintain a target white blood cells (WBC) between 2.0-3.0 × 109/L.</description>
    <arm_group_label>Antitumor drugs</arm_group_label>
    <other_name>Purinethol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients have been diagnosed with Acute Lymphoblastic Leukemia

          -  Childhood patients who were undergoing chemotherapy or continuous follow-up after
             completion of chemotherapy

          -  Patients received the phase of maintenance therapy that included oral 6-MP (&gt;4 weeks)
             and completion of ≥ 6 months according to the CCLG (Chinese Children's Leukemia Group)
             protocol-ALL 2015

        Exclusion Criteria:

          -  Patients with high-risk ALL (presence of higher-risk features: MRD ≥ 1% at 46 day, or
             age &lt; 6 month and white blood cell (WBC) count ≥ 300×109/L with translocations t(9;22)
             (q34;q11) [BCR-ABL], t(4;11) (q21;q23) [AF4/MLL], t(1;19) (q23;p13) [E2A-PBX1] or
             other MLL-rearrangements) were removed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Zhao, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shandong University</affiliation>
  </overall_official>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 15, 2019</study_first_submitted>
  <study_first_submitted_qc>April 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2019</study_first_posted>
  <last_update_submitted>April 19, 2019</last_update_submitted>
  <last_update_submitted_qc>April 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Wei Zhao</investigator_full_name>
    <investigator_title>Head of department of clinical pharmacy and pharmacology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mercaptopurine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

